Tango Therapeutics, Inc.
TNGX
Rang in aandelen
#4544
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aandeelprijs
$27.18
Laatst gesynchroniseerd: 2026-07-31
Marktkapitalisatie
$3.38B
Verandering (1 dag)
-1.41%
Verandering (1 jaar)
202.34%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Categorie
Healthcare
Winst voor Tango Therapeutics, Inc. (TNGX)
Winst in Jun 2026 TTM: $-123.78M
Volgens de meest recente financiële verslagen van Tango Therapeutics, Inc. bedraagt de huidige winst van het bedrijf $-123.78M. In 2023 behaalde het bedrijf een winst van $-101.61M, een stijging ten opzichte van de winst van 2022, die $-108.12M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Tango Therapeutics, Inc. van 2019 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-123.78M | -4.85% |
| 2024 | $-130.09M | 28.03% |
| 2023 | $-101.61M | -6.02% |
| 2022 | $-108.12M | 86.60% |
| 2021 | $-57.94M | 11.49% |
| 2020 | $-51.97M | 268.73% |
| 2019 | $-14.10M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -4,361.41% |
US
|
|
| $-3.09B | 2,393.88% |
US
|
|
| $-4.02B | 3,144.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,675.86% |
NL
|
